vs

Side-by-side financial comparison of Pulmonx Corp (LUNG) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.

Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $20.6M, roughly 1.5× Pulmonx Corp). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs -66.3%, a 102.6% gap on every dollar of revenue. On growth, Ponce Financial Group, Inc. posted the faster year-over-year revenue change (37.6% vs -8.7%). Over the past eight quarters, Ponce Financial Group, Inc.'s revenue compounded faster (23.7% CAGR vs -0.5%).

Pulmonx Corp is a global medical tech firm focused on interventional pulmonology solutions. It develops minimally invasive endobronchial valves to treat severe COPD and emphysema, with products sold across North America, Europe, and Asia-Pacific for patients with advanced lung conditions.

Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.

LUNG vs PDLB — Head-to-Head

Bigger by revenue
PDLB
PDLB
1.5× larger
PDLB
$31.4M
$20.6M
LUNG
Growing faster (revenue YoY)
PDLB
PDLB
+46.3% gap
PDLB
37.6%
-8.7%
LUNG
Higher net margin
PDLB
PDLB
102.6% more per $
PDLB
36.3%
-66.3%
LUNG
Faster 2-yr revenue CAGR
PDLB
PDLB
Annualised
PDLB
23.7%
-0.5%
LUNG

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
LUNG
LUNG
PDLB
PDLB
Revenue
$20.6M
$31.4M
Net Profit
$-13.7M
$10.1M
Gross Margin
77.9%
Operating Margin
-40.9%
43.6%
Net Margin
-66.3%
36.3%
Revenue YoY
-8.7%
37.6%
Net Profit YoY
5.5%
245.6%
EPS (diluted)
$-0.33
$0.43

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LUNG
LUNG
PDLB
PDLB
Q1 26
$20.6M
Q4 25
$22.6M
$31.4M
Q3 25
$21.5M
$26.7M
Q2 25
$23.9M
$26.5M
Q1 25
$22.5M
$24.6M
Q4 24
$23.8M
$22.8M
Q3 24
$20.4M
$20.2M
Q2 24
$20.8M
$20.2M
Net Profit
LUNG
LUNG
PDLB
PDLB
Q1 26
$-13.7M
Q4 25
$-10.4M
$10.1M
Q3 25
$-14.0M
$6.5M
Q2 25
$-15.2M
$6.1M
Q1 25
$-14.4M
$6.0M
Q4 24
$-13.2M
$2.9M
Q3 24
$-14.1M
$2.4M
Q2 24
$-15.3M
$3.2M
Gross Margin
LUNG
LUNG
PDLB
PDLB
Q1 26
77.9%
Q4 25
77.6%
Q3 25
74.7%
Q2 25
72.1%
Q1 25
72.5%
Q4 24
74.0%
Q3 24
73.7%
Q2 24
73.7%
Operating Margin
LUNG
LUNG
PDLB
PDLB
Q1 26
-40.9%
Q4 25
-43.8%
43.6%
Q3 25
-66.9%
32.8%
Q2 25
-62.0%
30.2%
Q1 25
-64.6%
32.5%
Q4 24
-56.5%
19.6%
Q3 24
-69.3%
15.2%
Q2 24
-75.2%
21.8%
Net Margin
LUNG
LUNG
PDLB
PDLB
Q1 26
-66.3%
Q4 25
-46.1%
36.3%
Q3 25
-64.9%
24.3%
Q2 25
-63.6%
23.0%
Q1 25
-64.1%
24.2%
Q4 24
-55.4%
14.1%
Q3 24
-69.4%
12.1%
Q2 24
-73.7%
15.8%
EPS (diluted)
LUNG
LUNG
PDLB
PDLB
Q1 26
$-0.33
Q4 25
$-0.25
$0.43
Q3 25
$-0.34
$0.27
Q2 25
$-0.38
$0.25
Q1 25
$-0.36
$0.25
Q4 24
$-0.33
$0.11
Q3 24
$-0.36
$0.10
Q2 24
$-0.39
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LUNG
LUNG
PDLB
PDLB
Cash + ST InvestmentsLiquidity on hand
$61.6M
$126.2M
Total DebtLower is stronger
$37.3M
$596.1M
Stockholders' EquityBook value
$45.8M
$541.5M
Total Assets
$120.0M
$3.2B
Debt / EquityLower = less leverage
0.82×
1.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LUNG
LUNG
PDLB
PDLB
Q1 26
$61.6M
Q4 25
$69.8M
$126.2M
Q3 25
$76.5M
$146.6M
Q2 25
$75.5M
$126.6M
Q1 25
$74.6M
$129.9M
Q4 24
$70.9M
$139.8M
Q3 24
$63.3M
$155.8M
Q2 24
$63.5M
$103.2M
Total Debt
LUNG
LUNG
PDLB
PDLB
Q1 26
$37.3M
Q4 25
$37.1M
$596.1M
Q3 25
$37.1M
$521.1M
Q2 25
$37.1M
$536.1M
Q1 25
$37.2M
$521.1M
Q4 24
$37.2M
$596.1M
Q3 24
$37.2M
$580.4M
Q2 24
$37.2M
$680.4M
Stockholders' Equity
LUNG
LUNG
PDLB
PDLB
Q1 26
$45.8M
Q4 25
$54.1M
$541.5M
Q3 25
$60.0M
$529.8M
Q2 25
$69.1M
$521.1M
Q1 25
$77.7M
$513.9M
Q4 24
$85.8M
$505.5M
Q3 24
$93.9M
$504.6M
Q2 24
$101.2M
$497.7M
Total Assets
LUNG
LUNG
PDLB
PDLB
Q1 26
$120.0M
Q4 25
$129.3M
$3.2B
Q3 25
$138.3M
$3.2B
Q2 25
$147.2M
$3.2B
Q1 25
$150.7M
$3.1B
Q4 24
$162.8M
$3.0B
Q3 24
$167.4M
$3.0B
Q2 24
$172.6M
$2.8B
Debt / Equity
LUNG
LUNG
PDLB
PDLB
Q1 26
0.82×
Q4 25
0.69×
1.10×
Q3 25
0.62×
0.98×
Q2 25
0.54×
1.03×
Q1 25
0.48×
1.01×
Q4 24
0.43×
1.18×
Q3 24
0.40×
1.15×
Q2 24
0.37×
1.37×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LUNG
LUNG
PDLB
PDLB
Operating Cash FlowLast quarter
$55.6M
Free Cash FlowOCF − Capex
$54.6M
FCF MarginFCF / Revenue
173.9%
Capex IntensityCapex / Revenue
3.1%
Cash ConversionOCF / Net Profit
5.48×
TTM Free Cash FlowTrailing 4 quarters
$74.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LUNG
LUNG
PDLB
PDLB
Q1 26
Q4 25
$-7.1M
$55.6M
Q3 25
$-8.2M
$1.4M
Q2 25
$-3.9M
$6.2M
Q1 25
$-13.2M
$13.1M
Q4 24
$-6.7M
$7.2M
Q3 24
$-7.2M
$-14.6M
Q2 24
$-5.8M
$-2.6M
Free Cash Flow
LUNG
LUNG
PDLB
PDLB
Q1 26
Q4 25
$-7.1M
$54.6M
Q3 25
$-8.3M
$786.0K
Q2 25
$-4.0M
$5.9M
Q1 25
$-13.5M
$12.9M
Q4 24
$-6.8M
$4.5M
Q3 24
$-7.7M
$-15.0M
Q2 24
$-6.2M
$-2.6M
FCF Margin
LUNG
LUNG
PDLB
PDLB
Q1 26
Q4 25
-31.4%
173.9%
Q3 25
-38.4%
2.9%
Q2 25
-16.6%
22.4%
Q1 25
-60.0%
52.6%
Q4 24
-28.8%
19.7%
Q3 24
-37.6%
-74.1%
Q2 24
-30.0%
-13.0%
Capex Intensity
LUNG
LUNG
PDLB
PDLB
Q1 26
Q4 25
0.1%
3.1%
Q3 25
0.4%
2.3%
Q2 25
0.2%
1.0%
Q1 25
1.3%
0.6%
Q4 24
0.5%
11.9%
Q3 24
2.0%
2.0%
Q2 24
2.3%
0.3%
Cash Conversion
LUNG
LUNG
PDLB
PDLB
Q1 26
Q4 25
5.48×
Q3 25
0.21×
Q2 25
1.01×
Q1 25
2.20×
Q4 24
2.46×
Q3 24
-5.99×
Q2 24
-0.80×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons